… in phase 2 and 3 studies, leading to the approval of OCR for the treatment of patients with
relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). …

… switching from placebo, earlier and continuous ocrelizumab treatment … ocrelizumab in
primary progressive disease, progression remains an important unmet need in multiple sclerosis. …

… ocrelizumab (Ocrevus®) was approved for the treatment of primary progressive multiple
sclerosis (… Real-world data about the clinical effectiveness of ocrelizumab has yet to be gathered. …

… However, in about 10% of the cases, the disease starts with a progressive disability worsening
without remission periods. This form of the disease is known as primary progressive MS (…

… To compare the clinical and radiological effectiveness of ocrelizumab in primary progressive
multiple sclerosis (PPMS) and relapsing-remitting multiple sclerosis (RRMS) in a clinical …

… active primary progressive multiple sclerosis (PPMS) were included in this prospective,
uncontrolled, open-label, observational study. All patients were followed by the Multiple Sclerosis …

… Ocrelizumab is a humanized monoclonal antibody that selectively targets CD20-positive
B … relapsing forms of multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS). …

… Ocrelizumab is a recombinant humanized monoclonal … effect of ocrelizumab on primary
progressive multiple sclerosis (… We aimed to assess the clinical effectiveness of ocrelizumab in …

… Ocrelizumab, an antiCD-20 antibody, is the only drug approved to treat patients with primary
progressive multiple sclerosis (pwPPMS). Not all candidates receive this treatment due to …

… Clinical evidence for ocrelizumab in primary progressive multiple sclerosis (PPMS) came
from a randomised controlled trial. From this trial, the European Medical Agency label …